Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation Helocyte, a majority-owned subsidiary of Fortress Biotech, is developing Triplex for the prevention and treatment of cytomegalovirus in multiple transplant indications, as well as HIV Clinical trial...

A Groundbreaking Milestone in the Treatment of NASH and Liver Fibrosis - Anervea Pune, March 17, 2024 (GLOBE NEWSWIRE) -- The recent FDA approval of Resmetirom, developed by Madrigal Pharmaceuticals, has sent ripples of excitement throughout the medical community, marking a...

Liver Transplantation Market at 7.1% CAGR to Reach US$2.4 Billion by 2030, Persistence Market Research New York, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The global liver transplantation market is projected to experience a compound annual growth rate (CAGR) of 7.1%, translating to an increase from US$ 1.5...

Fortress Biotech Subsidiary Helocyte Announces Grant that Could Provide Over $20 Million from National Institute of Allergy and Infectious Diseases for Phase 2 Study of Triplex for Control of Cytomegalovirus in Patients Undergoing Liver Transplantation MIAMI, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing...